Abstract 3753
Background
The advanced practice nurse (APN), with ability to apply evidence in an integrated framework, assumes new roles and acts as benchmark for patient and other professionals. In the last two decades, nurses have developed new advanced roles. There is international experience of the implementation for new model, and organizational ways by integrating and integrate interventions for EPA. High positive results in coordinating services and multidisciplinary teams, facilitate continuity of care resulting better quality of life and greater satisfaction for patients.
Methods
Descriptive study with patients treated in the functional unit of the Catalan Institute of Oncology in year 2018. After literature review on roles for nurses in lung cancer, we review number of interventions and activity carried out by EPA.
Results
A total of 589 first cases lung cancer started their first treatment. Nurse visited 93.2% of them in the Lung Functional Unit (LFU). Type of treatment; surgical 26.41%, palliative chemotherapy 11.83%, concomitant chemo+ radiotherapy in 11.65%, immunotherapy 4.19%, TKis 3.1%, sequential chemo+radiotherapy 3.2%, neoadjuvant chemo 1.58%, chemo+immunotherapy 0.27%, neoadjuvant chemo+radiotherapy+surgery in 0.15% and the rest 37.62% with supportive or palliative treatment. A total of 2563 visits by nurse, 21.42% were first visits, 73.23% patients with active treatment and 4.7% that have completed the treatment but with some toxicity. A total of 3935 phone calls were attended by nurses, of which 81.19% were patients who made calls and 18.80% were nurses on phone for control. Derivation was resulting to emergency for 5.13% of patients. 87.79% cases presented in Lung tumors board needed coordination for visits and for complementary proves.
Conclusions
Incorporate the EPA in the multidisciplinary care helps to minimize complications, to improve coordination and avoid deviations of the care process. Key activities were: health education to patient and family on care and self-care, improve the compression of the disease, the treatment and the process, strengthen information, minimize problems and improve resources for the care process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract